The meaning of "safe and effective"

Journal of the American Academy of Dermatology

Volumn 48, Issue 1, 2003, Pages 144-147

  Albrecht, Joerg ^a   Bigby, Michael ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0037236044     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.134     Document Type: Editorial

References (23)

1. Shaw B. The doctor's dilemma. London: Penguin; 1957. p. 26-7.
2. Li VW, Jaffe MP, Li WW, Haynes HA. Off-label dermatologic therapies. Arch Dermatol 1998;134:1449-54.
3. Bernhard JD. No further studies required: additional notes on avoiding manuscript rejection. J Am Acad Dermatol 2001;44:541-2.
4. Anonymous. Food and Drug Administration Bureau of drugs staff manual guide. G.T. No. BD 80-23 1980.
5. Anonymous. Milestones in U.S. food and drug law history. U.S. Food and Drug Administration Publication BG 95-1 1995.
6. US Department of Health, FDA, CDER, and CBER. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. May 1998.
7. Clinton B, Gore A. Reinventing regulation of drugs and medical devices. U.S. Food and Drug Administration National Performance Review, 1995.
8. Routledge PA. Adverse drug reactions and interactions: mechanisms, risk factors, detection, management and avoidance. In: Stephens MDB, Talbot JCC, Routledge PA, editors. Detection of new adverse drug reactions. London: Macmillan; 1998. p. 60-86.
9. International Conference of Harmonisation. Note for guidance E1 A population exposure: the extent of population exposure to assess clinical safety. November 1994.
10. Rowley-Jones D, Nicholson PA. Development of medicines: full development. In: Griffin JD, O'Grady J, D'Arcy PF, editors. The textbook of pharmaceutical medicine. Belfast: Queen's University of Belfast; 1998. p. 233-50.
11. Sackett D, Richardson W, Rosenberg W, Haynes R. Evidencebased medicine: how to practice and teach EBM. Edinburgh: Churchill Livingstone; 1996. p. 250.
12. Greenhalgh T. How to read a paper: the basics of evidence based medicine. London: BMJ Publishing Group; 1997. p. 196.
13. Jenicek M. Clinical case reporting in evidence-based medicine. Oxford: Butterworth-Heinemann, 1999.
14. Fazzari M, Heller G, Scher HI. The phase II/III transition: towards the proof of efficacy in cancer clinical trials. Control Clin Trials 2000;21:360-8.
15. Roujeau JC, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
16. Nisbett R, Ross L. Human inference: strategies and shortcomings of social judgement. Englewood Cliffs (NJ): Prentice-Hall; 1980. p. 62.
17. Leventhal JM, Hutchinson TA, Kramer MS, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions III. Results of tests among clinicians. JAMA 1979;242:1991-4.
18. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA 1975;234:1236-41.
19. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AM. An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA 1979;242:633-8.
20. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AM. An algorithm for the operational assessment of adverse drug reactions. I. Background, description and instruction for use. JAMA 1979;242:623-32.
21. Spilker B. Guide to clinical studies and developing protocols. New York: Raven Press; 1984. p. 302.
22. Lentner C, editor. Geigy scientific tables, introduction to statistics statistical tables mathematical formulae. Basel: Geigy; 1982. p. 240.
23. Runkle CL. Implications of the statement: no side effects were observed. N Engl J Med 1975;292:372-5.